BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial

Reuters02-21

Feb 21 (Reuters) - Neurosense Therapeutics Ltd :

* NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL

* NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS

* NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1

* NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024

* NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Sky Tgr
04-03
Sky Tgr
Super underrated 💎

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2413426081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-21 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2413426081","market":"us","top_or_hot":-1,"title":"BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial","media":"Reuters","content":"<html><body><p>Feb 21 (Reuters) - <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>   :</p><p>   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL</p><p>   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS</p><p>   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1</p><p>   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024</p><p>   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-21 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 21 (Reuters) - Neurosense Therapeutics Ltd   :   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2413426081","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2413426081","pubTimestamp":1708522740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 21  - Neurosense Therapeutics Ltd   :   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSIONSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd","ON":"安森美半导体","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","BK4588":"碎股","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4141":"半导体产品","BK4512":"苹果概念","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H"},"translate_title":"简报——Neurosense报告ALS 2b期试验的其他阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9,"ON":0.86},"content_text":"Feb 21 (Reuters) - Neurosense Therapeutics Ltd   :   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":291364334825688,"gmtCreate":1712159789193,"gmtModify":1712159792849,"author":{"id":"4105164288302490","authorId":"4105164288302490","name":"Sky Tgr","avatar":"https://static.itradeup.com/news/2df38375a020643507d69e511e3afc6b","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"4105164288302490","authorIdStr":"4105164288302490"},"htmlText":"Super underrated 💎&nbsp;","listText":"Super underrated 💎&nbsp;","text":"Super underrated 💎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/291364334825688","repostId":2413426081,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2413426081"}